Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01725568
Other study ID # 60
Secondary ID
Status Completed
Phase N/A
First received November 6, 2012
Last updated November 19, 2014
Start date November 2012
Est. completion date October 2014

Study information

Verified date November 2014
Source Biotronik SE & Co. KG
Contact n/a
Is FDA regulated No
Health authority Slovakia: State Institute for Drug ControlAustria: Agency for Health and Food Safety
Study type Observational

Clinical Trial Summary

The BioMonitor is an implantable cardiac monitor used to automatically detect and record episodes of arrhythmia in patients with bradycardia, tachycardia, asystole and atrial fibrillation. The study will be conducted to support regulatory approvals outside of Europe. This BioMonitor Master study is designed to investigate the clinical efficacy and safety of the BioMonitor.


Recruitment information / eligibility

Status Completed
Enrollment 152
Est. completion date October 2014
Est. primary completion date October 2014
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Suspected cardiac arrhythmia OR Previous AF diagnosis OR AF diagnosis before or after ablation procedure OR Stroke of unknown origin.

Exclusion Criteria:

- Implanted ICD or cardiac pacemaker

- Allergy to patch electrodes

Study Design

Observational Model: Case-Only, Time Perspective: Prospective


Related Conditions & MeSH terms


Intervention

Device:
BioMonitor
Implantable cardiac monitor

Locations

Country Name City State
Germany University of Rostock Rostock

Sponsors (1)

Lead Sponsor Collaborator
Biotronik SE & Co. KG

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Other Sensitivity and Positive Predictive of episode detection Sensitivity and Positive Predictive Value of each automatically detected cardiac arrhythmia that was stored as subcutaneous electrocardiogram by the BioMonitor (6 week, 3 and 12 month follow-up data) 1 year No
Other Adverse events 1 year Yes
Primary SADE free-rate SADE free-rate > 90% at 3 month follow-up at 3 month follow-up Yes
Primary Rate of appropriate QRS detection Rate of appropriate QRS detection > 90% (based on comparison with Holter ECG recording) at 6 week follow-up No